ZF 887
Alternative Names: ZF-887Latest Information Update: 11 Apr 2022
Price :
$50 *
At a glance
- Originator Z Factor Limited
- Developer Centessa Pharmaceuticals
- Class Small molecules
- Mechanism of Action Alpha 1-antitrypsin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alpha 1-antitrypsin deficiency
Most Recent Events
- 04 Apr 2022 Discontinued - Preclinical for Alpha 1-antitrypsin deficiency in United Kingdom (PO) (Centessa pipeline, April 2022)
- 01 Jul 2021 Preclinical trials in Alpha 1-antitrypsin deficiency in United Kingdom (PO) (Centessa Pharmaceuticals' pipeline, July 2021)
- 21 Apr 2021 Pharmacodynamics data from a preclinical trial in Alpha 1-antitrypsin deficiency released by Centessa Pharmaceuticals